Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
216 participants
OBSERVATIONAL
2024-05-30
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome
NCT04266665
Improving Outcomes for Patients With Life-Threatening Neurologic Illness
NCT04189471
Multimodal Neuromonitoring in Acute Brain Injury
NCT06302244
Study of PbiO2 Variation by Body Temperature and Capnia in Severe Head Trauma Patients Treated With Targeted Temperature Control
NCT04109430
Multimodal Monitoring in Patients With Spontaneous Intracerebral Hemorrhage
NCT02326571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Central to this study is the quantitative assessment of hemodynamic stability using the Vasoactive-Inotropic Score (VIS) and the Total Inotrope Exposure (TIE) Score. The VIS will quantify the need for vasopressor and inotropic support, reflecting the severity of cardiovascular instability. At the same time, the TIE Score will measure the cumulative exposure to inotropic agents, providing a comprehensive evaluation of the overall cardiovascular burden. The primary aim of this study is to explore the relationship between the etiology of brain death and the pharmacologic cardiovascular support administered, as quantified by VIS and TIES scores. Additionally, the study will assess how these pharmacologic interventions differ in patients who have undergone decompressive surgery compared to those who have not.
This thesis aspires to make a significant contribution to the optimization of management strategies for patients diagnosed with brain death, aiming to enhance clinical decision-making and improve patient outcomes in this critically ill cohort.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Spontaneous subarachnoid hemorrhage and spontaneous intracerebral hemorrhage
VIS, TIES
The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
Group 2
Traumatic intracranial hemorrhage
VIS, TIES
The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
Group 3
Ischemic cerebrovascular events and hypoxic-ischemic brain injury (including cases of cardiac arrest, drowning, carbon monoxide poisoning, etc.)
VIS, TIES
The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VIS, TIES
The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a confirmed diagnosis of brain death based on a positive apnea test and/or neuroimaging findings.
* Patients with comprehensive and complete clinical data available in the hospital\'s medical records.
Exclusion Criteria
* Patients with incomplete clinical data in the medical records.
* Patients with moderate to severe heart failure.
* Patients with major organ injuries in addition to traumatic intracranial hemorrhage.
* Pregnant patients.
* Patients with significant comorbidities that could impact hemodynamic stability.
* Patients experiencing hemodynamic instability due to septic shock.
* Patients who were initially treated for brain injury at external facilities and later transferred to our hospital.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Antalya Training and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nilgun Kavrut Ozturk
Professor MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nilgun Kavrut Ozturk, Professor
Role: STUDY_CHAIR
University of Health Science Antalya Training and Research Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Health Sciences
Antalya, Muratpasa, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Flowers WM Jr, Patel BR. Persistence of cerebral blood flow after brain death. South Med J. 2000 Apr;93(4):364-70.
Belletti A, Lerose CC, Zangrillo A, Landoni G. Vasoactive-Inotropic Score: Evolution, Clinical Utility, and Pitfalls. J Cardiothorac Vasc Anesth. 2021 Oct;35(10):3067-3077. doi: 10.1053/j.jvca.2020.09.117. Epub 2020 Sep 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-CeylanM.Braindeath
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.